Phase II Study of Interim PET-CT Scan-guided Response Adapted Therapy in Hodgkin's Lymphoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
toxicity of escalated BEACOPP in advanced hodgkin's lymphoma with interim PET scan positivity
this is a pilot study looking at the feasibility of delivering escalated Beacopp in the Indian population where there is no data on the delivery of the same. So the investigators are soliciting a group of patients who have a high risk of failure as defined by interim PET positivity after 2 cycles of ABVD chemotherapy. The investigators look at toxicity issues of this high intensity protocol
Once every 6 months
Yes
Prasanth Ganesan, MD, DM
Principal Investigator
Cancer Institute (WIA) , Adyar, Chennai
India: Institutional Review Board
CIA-HL-1
NCT01304849
January 2011
September 2013
Name | Location |
---|